Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Mar. 2024, Chugai Pharmaceutical Co has a Sloan Ratio of -1.35%, indicating the company is in the safe zone and there is no funny business with accruals.
Chugai Pharmaceutical Co Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chugai Pharmaceutical Co's Sloan Ratio %
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Sloan Ratio % falls into.
Chugai Pharmaceutical Co Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Chugai Pharmaceutical Co's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Chugai Pharmaceutical Co's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 588.527 (Jun. 2023 ) + 524.691 (Sep. 2023 ) + 633.456 (Dec. 2023 ) + 496.607 (Mar. 2024 ) = $2,243 Mil.
Chugai Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 896.107 (Jun. 2023 ) + 211.674 (Sep. 2023 ) + 862.68 (Dec. 2023 ) + 673.568 (Mar. 2024 ) = $2,644 Mil.
Chugai Pharmaceutical Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -67.594 (Jun. 2023 ) + 13.474 (Sep. 2023 ) + 39.199 (Dec. 2023 ) + -215.22 (Mar. 2024 ) = $-230 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (OTCPK:CHGCF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Chugai Pharmaceutical Co has a Sloan Ratio of -1.35%, indicating the company is in the safe zone and there is no funny business with accruals.
Chugai Pharmaceutical Co Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.
Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHGCF has been successfully added to your 